LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF TOCILIZUMAB IN RITUXIMAB-REFRACTORY RHEUMATOID ARTHRITIS

被引：1
|
作者：
Farah, Z. [1 ]
Reddy, V. [2 ]
Ali, S. [1 ]
Price-Kuehne, F. [1 ]
Moore, S. [2 ]
Mackworth-Young, C. [1 ]
Ehrenstein, M. [2 ]
机构：
[1] Charing Cross Hosp, Rheumatol, London, England
[2] Univ Coll London Hosp, Rheumatol, London, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.4452
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0183
引用
收藏
页码：734 / 735
页数：2
相关论文
共 50 条
  • [21] TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: LONG-TERM EFFICACY FOR UP TO 3.5 YEARS
    Smolen, J. S.
    Gomez-Reino, J. J.
    Davies, C.
    Alecock, E.
    Rubbert-Roth, A.
    Emery, P.
    RHEUMATOLOGY, 2010, 49 : I110 - I111
  • [22] Safety and Efficacy Of Subcutaneous Tocilizumab Monotherapy In a Long-Term Extension Study In Japanese Rheumatoid Arthritis Patients.
    Ogata, Atsushi
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S605 - S606
  • [23] Rofecoxib demonstrates long-term safety and tolerability in juvenile rheumatoid arthritis (JRA)
    Goodman, S
    Ferrandiz, M
    Kiss, MH
    Rose, ES
    Chen, PY
    Frontera, N
    Bolognese, JA
    Reicin, AS
    van Adelsberg, J
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S94 - S95
  • [24] LONG-TERM SAFETY OF RITUXIMAB: FOLLOW UP OF THE RHEUMATOID ARTHRITIS CLINICAL TRIALS
    van Vollenhoven, Ronald
    Emery, Paul
    Bingham, Clifton, III
    Keystone, Edward
    Fleischmann, Roy M.
    Furst, Daniel E.
    Macey, Katherine M.
    Sweetser, Marianne T.
    Lehane, Patricia
    Farmer, Pamela
    Long, Simon G.
    RHEUMATOLOGY, 2011, 50 : 127 - 128
  • [25] Extended follow-up of the long-term safety of rituximab in rheumatoid arthritis
    Emery, Paul
    van Vollenhoven, Ronald F.
    Binghamlll, Clifton O.
    Keystone, Edward C.
    Greenwald, Maria
    Moreland, Larry W.
    Sweetser, Marianne
    Rowe, Karen
    Wagner, Bridget
    Magrini, Fabio
    RHEUMATOLOGY, 2008, 47 : II16 - II16
  • [26] Extended follow-up of the long-term safety of rituximab in rheumatoid arthritis
    van Vollenhoven, Ronald
    Haraoui, Boulos
    Emery, Paul
    Bingham, Clifton
    Keystone, Edward
    Greenwald, Maria
    Moreland, Larry
    Sweetser, Marianne
    Rowe, Karen
    Wagner, Bridget
    Magrini, Fabio
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (06) : 1187 - 1188
  • [27] LONG-TERM EXTENSION STUDIES OF TOCILIZUMAB IN RA: SAFETY AND TOLERABILITY
    Genovese, Mark C.
    Sebba, Anthony
    Rubbert-Roth, Andrea
    Scali, Juan
    Zilberstein, Moshe
    Vernon, Emma
    Vollenhoven, Ronald
    RHEUMATOLOGY, 2011, 50 : 33 - 33
  • [28] LONG-TERM EFFICACY AND SAFETY OF RITUXIMAB IN SYSTEMIC SCLEROSIS REFRACTORY TO CONVENTIONAL IMMUNOSUPPRESSANTS
    Polito, P.
    Zanatta, E.
    Favaro, M.
    Felicetti, M.
    Oliviero, F.
    Pigatto, E.
    Cozzi, F.
    Doria, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1530 - 1530
  • [29] Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus
    Catapano, Fausta
    Chaudhry, Afzal N.
    Jones, Rachel B.
    Smith, Kenneth G. C.
    Jayne, David W.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (11) : 3586 - 3592
  • [30] Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study
    Kivitz A.
    Wallace T.
    Olech E.
    Borofsky M.
    Devenport J.
    Pei J.
    Michalska M.
    Rheumatology and Therapy, 2016, 3 (2) : 291 - 304
12345